Patents by Inventor Robert N. Young

Robert N. Young has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6121253
    Abstract: This invention relates to prostaglandin-bisphosphonate conjugates. These conjugates are effective for treating or preventing bone diseases such as osteoporosis. These conjugates simultaneously deliver a prostaglandin agent for increasing bone formation and a bisphosphonate agent for inhibiting bone resorption.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: September 19, 2000
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yongxin Han, Robert N. Young, Laurent Gil, Rejean Ruel
  • Patent number: 6034089
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV). ##STR1## The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula I.
    Type: Grant
    Filed: September 28, 1998
    Date of Patent: March 7, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Yongxin Han, Andre Giroux, Dwight MacDonald, Robert N. Young, Helene Perrier, Carole Lepine
  • Patent number: 6020339
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV). ##STR1## The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula I.
    Type: Grant
    Filed: September 28, 1998
    Date of Patent: February 1, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Helene Perrier, Yongxin Han, Christopher Bayly, Dwight Mac Donald, Andre Giroux, Robert N. Young
  • Patent number: 5472964
    Abstract: Compounds having the formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: December 5, 1995
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Marc Labelle, Yves Leblanc, Yi B. Xiang, Cheuk K. Lau, Claude Dufresne, Yves Gareau
  • Patent number: 5428171
    Abstract: Compounds having the formula: ##STR1## are antagonists of leukotrienes and inhibitors of their biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.
    Type: Grant
    Filed: May 26, 1989
    Date of Patent: June 27, 1995
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Robert Zamboni, Serge Leger
  • Patent number: 5410054
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: July 20, 1993
    Date of Patent: April 25, 1995
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Rick Friesen, Robert N. Young, Yves Girard, Marc Blouin, Daniel Dube
  • Patent number: 5409911
    Abstract: This invention relates to a prostaglandin-bisphosphonate compound of the formula: ##STR1## and its pharmaceutically acceptable salts. The claimed compounds are effective as delivery agents of prostaglandins to treat osteoporosis and related bone diseases. The claimed compounds also simultaneously deliver a bisphosphonate which inhibits bone resorption and delivers prostaglandins which increase bone formation in vivo.
    Type: Grant
    Filed: September 11, 1992
    Date of Patent: April 25, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Peter C. Tyler, Robert N. Young, Gideon A. Rodan
  • Patent number: 5391044
    Abstract: Lifting and towing apparatus for attachment to a towing vehicle having a winch thereon and the frame of which includes a pair of spaced apart longitudinal beams at least partially supported on a rear axle of said vehicle. The apparatus includes a support assembly extending transversely between the vehicle beams and opposite outer ends of which are attachable to opposing ones of the beams directly above the rear axle. An arm assembly extends rearwardly from the support assembly and has at least one lifting connection for connection to the winch and by which the distal end of the arm assembly may be lifted. A cradle assembly is connected to the distal end of the arm assembly for securing the front or rear wheels of a towed vehicle thereto for lifting above the ground in response to lifting of the distal end of the arm assembly by the winch.
    Type: Grant
    Filed: April 22, 1993
    Date of Patent: February 21, 1995
    Inventor: Robert N. Young
  • Patent number: 5281720
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: October 26, 1992
    Date of Patent: January 25, 1994
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Yves Girard, John W. Gillard, Laird A. Trimble, John Scheigetz, James A. Yergey, Yves Ducharme, Deborah A. Nicoll-Griffith, John H. Hutchinson
  • Patent number: 5232916
    Abstract: Compounds having the formula: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: October 28, 1991
    Date of Patent: August 3, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert Zamboni, Petpiboon Prasit, Robert N. Young
  • Patent number: 5227399
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: October 26, 1992
    Date of Patent: July 13, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Yves Girard, John W. Gillard, Laird A. Trimble, John Scheigetz, James A. Yergey, Yves Ducharme, Deborah A. Nicoll-Griffith, John H. Hutchinson
  • Patent number: 5204358
    Abstract: Compounds having the formula: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.
    Type: Grant
    Filed: January 9, 1992
    Date of Patent: April 20, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Robert Zamboni, Jacques-Yves Gauthier, Michel L. Belley
  • Patent number: 5136034
    Abstract: Thioacids, thiols, an acid, and an aldehyde are used to produce chiral thioacetals of the general formula. ##STR1## The compounds are leukotriene antagonists.
    Type: Grant
    Filed: October 5, 1990
    Date of Patent: August 4, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Michel Therien, Jacques-Yves Gauthier, Robert Zamboni, Michel L. Belley
  • Patent number: 5118858
    Abstract: Disclosed herein are /.sup.35 S/-labelled compound of the formula (I):(C.sub.6 H.sub.5).sub.3 C.sup.35 SHand processes therefor. This Compound (I) is useful as an intermediate for the introduction of sulfur isotope into a variety of compounds. For example, it is useful in the introduction of sulfur isotope into important compounds such as 6-mercaptopurine, 5-[3-(2-(7-chloroquinolin-2-yl)ethenyl)phenyl]-8-dimethylcarbamyl-4,6-dith ioactanoic acid, a potent antagonist of leukotriene D.sub.4 ; thiophosphoric acid derivatives, photo-affinity reagents and the like.
    Type: Grant
    Filed: October 19, 1990
    Date of Patent: June 2, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Haydn W. R. Williams, Robert N. Young, Robert J. Zamboni
  • Patent number: 5104882
    Abstract: Compounds having the formula: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.
    Type: Grant
    Filed: May 22, 1990
    Date of Patent: April 14, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Robert Zamboni, Jacques-Yves Gauthier, Michel L. Belley
  • Patent number: 5102881
    Abstract: Compounds having the formula: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: December 20, 1989
    Date of Patent: April 7, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert Zamboni, Petpiboon Prasit, Robert N. Young
  • Patent number: 5091533
    Abstract: Compounds of the formula: ##STR1## where R.sup.2 contains certain aryls or heteroaryls are effective leukotriene inhibitors.
    Type: Grant
    Filed: March 12, 1990
    Date of Patent: February 25, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Patrice C. Belanger, Claude Dufresne, Brian Fitzsimmons, deceased, Maryann Fitzsimmons, Heir, Yvan Guindon, Cheuk K. Lau, Joshua Rokach, John Schiegetz, Michel Therien, Robert N. Young
  • Patent number: 5037840
    Abstract: Compounds having the formula: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful an anti-asthmatic, antiallergic, anti-inflammatory, and cytoprotective agents.
    Type: Grant
    Filed: March 5, 1990
    Date of Patent: August 6, 1991
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Robert Zamboni
  • Patent number: 5017583
    Abstract: Compounds of the Formula I: ##STR1## and pharmaceutically acceptable salts thereof are leukotriene antagonists. These compounds inhibit SRS-A and leukotriene synthesis and are antagonists of SRS-A and are thus useful in the treatment of asthma, allergic disorders, inflammation, skin diseases and certain cardiovascular disorders.
    Type: Grant
    Filed: February 23, 1988
    Date of Patent: May 21, 1991
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Joshua Rokach, Haydn R. Williams, Masatoshi Kakushima, Yvan Guindon
  • Patent number: 5004743
    Abstract: Compounds having the formula: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.
    Type: Grant
    Filed: November 25, 1987
    Date of Patent: April 2, 1991
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Robert Zamboni, Jacques Y. Gauthier